Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Depreciation & Amortization (CF) (2017 - 2025)

Historic Depreciation & Amortization (CF) for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $2.9 million.

  • Denali Therapeutics' Depreciation & Amortization (CF) rose 6033.73% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year increase of 2532.33%. This contributed to the annual value of $7.8 million for FY2024, which is 5336.6% down from last year.
  • Per Denali Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $2.9 million for Q3 2025, which was up 6033.73% from $3.0 million recorded in Q2 2025.
  • Denali Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $10.0 million during Q1 2023, with a 5-year trough of $1.8 million in Q3 2024.
  • For the 5-year period, Denali Therapeutics' Depreciation & Amortization (CF) averaged around $2.7 million, with its median value being $2.2 million (2023).
  • As far as peak fluctuations go, Denali Therapeutics' Depreciation & Amortization (CF) surged by 38326.12% in 2023, and later tumbled by 7848.11% in 2024.
  • Quarter analysis of 5 years shows Denali Therapeutics' Depreciation & Amortization (CF) stood at $2.1 million in 2021, then skyrocketed by 95.53% to $4.1 million in 2022, then tumbled by 47.01% to $2.2 million in 2023, then decreased by 14.65% to $1.9 million in 2024, then surged by 58.61% to $2.9 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $2.9 million for Q3 2025, versus $3.0 million for Q2 2025 and $2.3 million for Q1 2025.